March 3, 2026
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
AI and job cuts: What the block layoffs signal for pharma and beyond
February 27, 2026
UroGen lands $250M despite $153M loss — Are lenders right to bet on bladder cancer’s next blockbuster?
BioPharma Credit gets a bigger slice — and a $3M fee — as UroGen bets big on ZUSDURI
GSK purchases 35Pharma for $950M to expand into pulmonary hypertension
GlaxoSmithKline has entered into an agreement to acquire Canadian clinical-stage biotech 35Pharma Inc. for $950 million in cash, expanding its respiratory and cardiovascular pipeline, according to regulatory filings and the...
AI and job cuts: What the block layoffs signal for pharma and beyond
In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to artificial intelligence (AI) and automation — not just general cost-cutting. The biggest recent example comes from fintech firm Block Inc.,...
February 26, 2026
The ADC arms race: payload power vs targeting precision
Over the past decade, antibody-drug conjugates (ADCs) have emerged as a high-impact class of cancer therapies, blending the selectivity of...
February 25, 2026
Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental...
